中国麻风皮肤病杂志 ›› 2026, Vol. 42 ›› Issue (10): 716-721.doi: 10.12144/zgmfskin202610716

• 论著 • 上一篇    下一篇

度普利尤单抗治疗婴儿期中重度特应性皮炎疗效评价

杨晨晨,陈萍,周倩,徐玺环,李霞   

  1. 徐州医科大学附属徐州市儿童医院，江苏徐州，221006
  • 出版日期:2026-10-15 发布日期:2026-10-09

Clinical efficacy of dupilumab in infants with moderate-to-severe atopic dermatitis

YANG Chenchen, CHEN Ping, ZHOU Qian, XU Xihuan, LI Xia   

  1. Xuzhou Children's Hospital Affiliated to Xuzhou Medical University, Xuzhou 221006, China
  • Online:2026-10-15 Published:2026-10-09

PDF (PC)

23

摘要： 目的：明确度普利尤单抗治疗6个月至1岁婴儿中重度特应性皮炎(atopic dermatitis, AD)的疗效及安全性。方法：回顾性分析2023年6月至2026年4月徐州市儿童医院32例接受度普利尤单抗治疗并完成16周随访的6个月至1岁中重度AD患儿的临床特征，评估基线及治疗后第4、8、12、16周AD面积及严重程度指数（EASI）、研究者总体评估（IGA）、AD严重程度评分（SCORAD）、瘙痒数字评价量表（NRS）、婴儿皮肤病生活质量指数（IDQoL）及AD控制工具（ADCT）评分，并记录不良反应。结果：治疗16周时，32例患者EASI由19.80（17.38，22.18）分降至2.15（0.70，5.33）分；IGA由3.00（3.00，4.00）分降至1.00（1.00，2.00）分；其余评分均随治疗时间延长持续下降（均P＜0.001）。EASI 90达标组病程3.00（2.00，3.00）个月显著短于未达标组的6.00（4.50，7.00）个月（P＜0.001）；达标组病程≤3.5个月占比（76.5% vs 20.0%）及合并食物过敏者比例（58.8% vs 13.3%）均高于未达标组（均P＜0.05）。16周内4例（12.5%）患儿发生不良反应，其中结膜炎3例、发热1例，均自行缓解；未见严重不良反应。结论：度普利尤单抗在婴儿期中重度AD患儿中疗效及安全性表现良好。合并食物过敏及病程较短可能与疗效相关，但尚不能视为独立预测因素，未来仍需更大样本、长期随访研究进一步验证。

关键词: 度普利尤单抗, 特应性皮炎, 婴儿, 疗效, 安全性

Abstract: Objective: To evaluate the efficacy and safety of dupilumab in infants aged 6 months to 1 year with moderate-to-severe atopic dermatitis. Methods: A retrospective analysis was performed in 32 children aged 6 months to 1 year with moderate-to-severe atopic dermatitis who received dupilumab at Xuzhou Children's Hospital from June 2023 to April 2026 and completed 16 weeks of follow-up. Demographic and clinical data were collected. The Eczema Area and Severity Index (EASI), Investigator Global Assessment (IGA), SCORing Atopic Dermatitis (SCORAD), pruritus Numerical Rating Scale (NRS), Infants' Dermatitis Quality of Life Index (IDQoL), and Atopic Dermatitis Control Tool (ADCT) were assessed at baseline and at weeks 4, 8, 12, and 16. Adverse events were recorded. Results: At week 16, the EASI score decreased from 19.80 (17.38, 22.18) to 2.15 (0.70, 5.33). The IGA score decreased from 3.00 (3.00, 4.00) to 1.00 (1.00, 2.00). Other scores also decreased over time (all P＜0.001).The disease duration in the EASI 90 responder group was 3.00 (2.00, 3.00) months, which was significantly shorter than that in the non-responder group ［6.00 (4.50, 7.00) months］ (P ＜ 0.001). The proportions of patients with disease duration ≤3.5 months (76.5% vs 20.0%) and concomitant food allergy (58.8% vs 13.3%) were higher in the responder group than in the non-responder group (all P ＜ 0.05). Adverse events occurred in 4 children (12.5%). No serious adverse events were observed. Conclusion: Dupilumab showed good efficacy and safety in infants with moderate-to-severe atopic dermatitis.Comorbid food allergy and shorter disease duration may be associated with efficacy, but they cannot yet be regarded as independent predictors,further validation in larger studies with long-term follow-up is warranted.

Key words: dupilumab, atopic dermatitis, infant, efficacy, safety